Pfizer (NYSE:PFE) and Astellas Pharma (OTCPK:ALPMF) announced on Tuesday that their jointly developed antibody-drug conjugate ...

Can Boston stay on top in biotech? Find out on Sept 17, 6-9 p.m. EDT to explore talent shifts, funding, and Boston’s future.

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

Merck in 2019 inked a deal to evaluate the combination of its blockbuster cancer drug Keytruda with Pacdev from Astellas and Seagen, which Pfizer acquired in a $43 billion deal that closed in late ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...

The combination of Padcev, a bladder cancer drug from Pfizer Inc. and Astellas Pharma Inc., and Merck & Co.’s blockbuster immunotherapy Keytruda extended the lives of patients with a hard-to-treat ...

Astellas Pharma Inc. rose the most in more than three months after quarterly profit exceeded analysts’ projections, driven by robust sales of its Padcev cancer treatment and Mirabegron used to control ...

Astellas Pharma Inc., based in Tokyo, announced July 11 that it completed its previously announced $5.9 billion acquisition of Iveric Bio Inc., an early-stage biopharmaceutical company based in ...

Contacts Elpiscience Biopharma, Ltd. [email protected] Astellas Pharma Inc. Corporate Communications +81-3-3244-3201 ...

While it remains to be seen if pop superstar Taylor Swift will attend Super Bowl LVIII, we know Astellas Pharma will be there. The Japanese drugmaker announced Thursday morning that it will run a ...